Our top pick for
Orthofix Medical Inc is a medical devices business based in the US. Orthofix Medical shares (OFIX) are listed on the NASDAQ and all prices are listed in US Dollars. Orthofix Medical employs 1,036 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$36.57|
|52-week range||$30.59 - $48.50|
|50-day moving average||$39.38|
|200-day moving average||$40.74|
|Wall St. target price||$54.38|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.42|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||0.61%|
|1 month (2021-09-22)||-7.09%|
|3 months (2021-07-22)||-3.31%|
|6 months (2021-04-22)||-18.08%|
|1 year (2020-10-21)||9.43%|
|2 years (2019-10-21)||-30.84%|
|3 years (2018-10-19)||56.77|
|5 years (2016-10-21)||39.57|
Valuing Orthofix Medical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Orthofix Medical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Orthofix Medical's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 4.1. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Orthofix Medical's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Orthofix Medical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $45 million.
The EBITDA is a measure of a Orthofix Medical's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$455.6 million|
|Operating margin TTM||2.01%|
|Gross profit TTM||$304.7 million|
|Return on assets TTM||1.04%|
|Return on equity TTM||-2.3%|
|Market capitalisation||$713.7 million|
TTM: trailing 12 months
There are currently 411,856 Orthofix Medical shares held short by investors – that's known as Orthofix Medical's "short interest". This figure is 15.3% up from 357,139 last month.
There are a few different ways that this level of interest in shorting Orthofix Medical shares can be evaluated.
Orthofix Medical's "short interest ratio" (SIR) is the quantity of Orthofix Medical shares currently shorted divided by the average quantity of Orthofix Medical shares traded daily (recently around 78598.473282443). Orthofix Medical's SIR currently stands at 5.24. In other words for every 100,000 Orthofix Medical shares traded daily on the market, roughly 5240 shares are currently held short.
However Orthofix Medical's short interest can also be evaluated against the total number of Orthofix Medical shares, or, against the total number of tradable Orthofix Medical shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Orthofix Medical's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Orthofix Medical shares in existence, roughly 20 shares are currently held short) or 0.0215% of the tradable shares (for every 100,000 tradable Orthofix Medical shares, roughly 22 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Orthofix Medical.
Find out more about how you can short Orthofix Medical stock.
We're not expecting Orthofix Medical to pay a dividend over the next 12 months.
Over the last 12 months, Orthofix Medical's shares have ranged in value from as little as $30.59 up to $48.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Orthofix Medical's is 1.1413. This would suggest that Orthofix Medical's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Extremities. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures. This segment also designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and a portfolio of regenerative products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions. The Global Extremities segment designs, develops, and markets orthopedic products that are used in fracture repair, deformity correction, and bone reconstruction procedures. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.